Patents by Inventor Cho-Rok Jung
Cho-Rok Jung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11732232Abstract: The present disclosure provides a biomimetic cell culture apparatus that mimics interactions among organs in a human body. The present disclosure includes a plurality of culture units for culturing cells, a conduit for connecting the plurality of culture units to each other to form a circulating path, a pump unit disposed on the conduit for forming a flow in culture medium such that the culture medium circulates through the plurality of culture units, and an agitating module for agitating the plurality of culture units.Type: GrantFiled: August 14, 2020Date of Patent: August 22, 2023Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Cho Rok Jung, Jung Hwa Lim, Hyun Mi Kang, Kyung Hee Noh, Kyung Sook Chung, Mi Young Son, Myung Jin Son
-
Publication number: 20230000923Abstract: The present invention relates to a method for producing induced dopaminergic neuronal progenitors from adult cells using direct reprogramming, induced dopaminergic neuronal progenitors produced via the method and a use for same, wherein, as a result of having been directly reprogrammed from adult cells, the induced dopaminergic neuronal progenitors produced by means of the present invention can be transplanted inside a living body without the risk of oncogenicity, and have excellent proliferative capacity and dopaminergic neuronal differentiation potency, thus can be usefully utilized as a cell therapy product for Parkinson's disease.Type: ApplicationFiled: September 21, 2020Publication date: January 5, 2023Inventors: Janghwan KIM, Minhyung LEE, Mi Young SON, Young Joo JEON, Areum BAEK, Young Jeon LEE, Jincheol SEO, Cho Rok JUNG
-
Publication number: 20220308045Abstract: The present invention relates to expandable liver organoids, a medium composition for differentiation thereof, and a method for producing liver organoids using the same, and the liver organoids according to the present invention exhibit the characteristics of more mature hepatocytes than 2D differentiated hepatocytes, can be subcultured up to 90 times or more, and exhibit the expandability for maintaining the characteristics of mature hepatocytes even after multiple subcultures, and thus can be usefully utilized for predicting toxicity, regeneration, and inflammatory response, drug screening, and modeling of diseases such as hepatic steatosis.Type: ApplicationFiled: March 4, 2022Publication date: September 29, 2022Inventors: Myung Jin SON, Kyung-Sook CHUNG, Seonju MUN, Jae Sung RYU, Cho-Rok JUNG, Hyun-Soo CHO, Dae Soo KIM
-
Publication number: 20220135950Abstract: The present invention relates to a method for preparing a human intestinal epithelial model. The human intestinal epithelial model, prepared by the method according to the present invention, has all characteristics of goblet cells, enteroendocrine cells, and Paneth cells, and thus can highly mimic the function of actual human intestinal cells, so that the human intestinal epithelial model can be effectively used for development of new drugs, evaluation of drug absorption and toxicity, or evaluation of engraftment of intestinal microorganisms, or as a composition for in vivo transplantation.Type: ApplicationFiled: April 15, 2021Publication date: May 5, 2022Inventors: Mi Young SON, Ohman KWON, Kwang Bo JUNG, Kyeong-Ryoon LEE, Cho Rok JUNG, Janghwan KIM
-
Publication number: 20220135949Abstract: The present invention relates to a method for preparing a human intestinal epithelial model. The human intestinal epithelial model, prepared by the method according to the present invention, has all characteristics of goblet cells, enteroendocrine cells, and Paneth cells, and thus can highly mimic the function of actual human intestinal cells, so that the human intestinal epithelial model can be effectively used for development of new drugs, evaluation of drug absorption and toxicity, or evaluation of engraftment of intestinal microorganisms, or as a composition for in vivo transplantation.Type: ApplicationFiled: November 3, 2020Publication date: May 5, 2022Inventors: Mi Young SON, Ohman KWON, Kwang Bo JUNG, Kyeong-Ryoon LEE, Cho Rok JUNG, Janghwan KIM
-
Publication number: 20220049205Abstract: The present disclosure provides a biomimetic cell culture apparatus that mimics interactions among organs in a human body. The present disclosure includes a plurality of culture units for culturing cells, a conduit for connecting the plurality of culture units to each other to form a circulating path, a pump unit disposed on the conduit for forming a flow in culture medium such that the culture medium circulates through the plurality of culture units, and an agitating module for agitating the plurality of culture units.Type: ApplicationFiled: August 14, 2020Publication date: February 17, 2022Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Cho Rok JUNG, Jung Hwa LIM, Hyun Mi KANG, Kyung Hee NOH, Kyung Sook CHUNG, Mi Young SON, Myung Jin SON
-
Publication number: 20210017483Abstract: A cell culture vessel according to the present invention is characterized by comprising a first vessel having a stirring member disposed therein, and a second vessel configured to be inserted in the interior of the first vessel and having a hole for allowing a solvent accommodated in the first vessel to pass through the interior thereof, wherein the stirring member is arranged in a recess portion formed in the first vessel.Type: ApplicationFiled: September 6, 2017Publication date: January 21, 2021Inventors: Sun Woong KANG, Sang Soo HAN, Cho Rok JUNG, Kyung Sook CHUNG
-
Publication number: 20200115683Abstract: Provided are a method of preparing in vitro-matured intestinal organoids, and intestinal organoids prepared by the method.Type: ApplicationFiled: October 10, 2019Publication date: April 16, 2020Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Mi Young Son, Janghwan Kim, Soo Jin Oh, Cho Rok Jung, Hyun Soo Cho, Hana Lee, Kwang Bo Jung
-
Publication number: 20150191687Abstract: The present invention relates to a cell culture container comprisng: an outer container of which an upper surface is open and into which a culture solution can be put; a container cover coupled to the upper end of the outer container to prevent the penetration of microorganisms; and an inner container which is placed inside the outer container, can put a culture solution, and can be separated from the outer container. The present invention relates to a cultivation culture system comprising: a plurality of the cell culture containers; circulation pipes for connecting each of the adjacent cell culture containers so as to allow the plurality of the cell culture containers to be interconnected and connecting a pair of the cell culture containers placed at both ends; and a circulation portion for supplying a culture solution and gas to a cell culture portion so as to circulate the same.Type: ApplicationFiled: October 17, 2013Publication date: July 9, 2015Inventors: Cho-Rok Jung, Jung Hwa Lim, Dong-Soo Im
-
Patent number: 9066976Abstract: The present invention relates to the E2EPF UCP-VHL interaction and the uses thereof, more precisely a method for increasing or reducing VHL activity or level by regulating UCP activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of UCP activity is accomplished by any UCP activity inhibitor selected from a group consisting of a small interfering RNA (RNAi), an antisense oligonucleotide, and a polynucleotide complementarily binding to mRNA of UCP, a peptide, a peptide mimetics and an antibody, and a low molecular compound. In the meantime, the increase of angiogenesis is accomplished by the following mechanism; UCP over-expression is induced by a gene carrier and thus endogenous VHL is reduced, leading to the stabilization of HIF-1? which enhances VEGF activation based on the HIF-1? stabilization.Type: GrantFiled: August 22, 2011Date of Patent: June 30, 2015Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Dong-Soo Im, Cho-Rok Jung, Kyung-Sun Hwang, Jung Hwa Lim
-
Patent number: 9056132Abstract: The present invention relates to the E2EPF UCP-VHL interaction and the uses thereof, more precisely a method for increasing or reducing VHL activity or level by regulating UCP activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of UCP activity is accomplished by any UCP activity inhibitor selected from a group consisting of a small interfering RNA (RNAi), an antisense oligonucleotide, and a polynucleotide complementarily binding to mRNA of UCP, a peptide, a peptide mimetics and an antibody, and a low molecular compound. In the meantime, the increase of angiogenesis is accomplished by the following mechanism; UCP over-expression is induced by a gene carrier and thus endogenous VHL is reduced, leading to the stabilization of HIF-1? which enhances VEGF activation based on the HIF-1? stabilization.Type: GrantFiled: February 18, 2014Date of Patent: June 16, 2015Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Dong-Soo Im, Cho-Rok Jung, Kyung-Sun Hwang, Jung Hwa Lim
-
Publication number: 20140234285Abstract: The present invention relates to the E2EPF UCP-VHL interaction and the uses thereof, more precisely a method for increasing or reducing VHL activity or level by regulating UCP activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of UCP activity is accomplished by any UCP activity inhibitor selected from a group consisting of a small interfering RNA (RNAi), an antisense oligonucleotide, and a polynucleotide complementarily binding to mRNA of UCP, a peptide, a peptide mimetics and an antibody, and a low molecular compound. In the meantime, the increase of angiogenesis is accomplished by the following mechanism; UCP over-expression is induced by a gene carrier and thus endogenous VHL is reduced, leading to the stabilization of HIF-1? which enhances VEGF activation based on the HIF-1? stabilization.Type: ApplicationFiled: February 18, 2014Publication date: August 21, 2014Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Dong-Soo IM, Cho-Rok JUNG, Kyung-Sun HWANG, Jung Hwa Lim
-
Patent number: 8404435Abstract: The present invention relates to Enigma (PDLIM7)-Mdm2 interaction and use thereof. More particularly, it may induce an effective apoptosis of cancer cells by inhibition of an Enigma expression or an Enigma activity which induces Mdm2 destabilization and p53 activity; it may assess the prognosis of anti-cancer therapy by determining that Enigma, which is induced by SRF, is overexpressed in cancer tissues with Mdm2; it may screen anti-cancer activity substances by selecting a factor to inhibit specific binding between Enigma and Mdm2. Enigma-Mdm2 interaction and Enigma expression regulation may be utilized usefully for preventing cancers and developing therapeutic methods and anti-cancer agents.Type: GrantFiled: September 22, 2011Date of Patent: March 26, 2013Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Cho-Rok Jung, Dong-Soo Im, Jung-Hwa Lim, Yoon Jung Choi
-
Publication number: 20120107297Abstract: The present invention relates to the E2EPF UCP-VHL interaction and the uses thereof, more precisely a method for increasing or reducing VHL activity or level by regulating UCP activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of UCP activity is accomplished by any UCP activity inhibitor selected from a group consisting of a small interfering RNA (RNAi), an antisense oligonucleotide, and a polynucleotide complementarily binding to mRNA of UCP, a peptide, a peptide mimetics and an antibody, and a low molecular compound. In the meantime, the increase of angiogenesis is accomplished by the following mechanism; UCP over-expression is induced by a gene carrier and thus endogenous VHL is reduced, leading to the stabilization of HIF-1? which enhances VEGF activation based on the HIF-1? stabilization.Type: ApplicationFiled: August 22, 2011Publication date: May 3, 2012Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Dong-Soo Im, Cho-Rok Jung, Kyung-Sun Hwang
-
Publication number: 20120015374Abstract: The present invention relates to Enigma (PDLIM7)-Mdm2 interaction and use thereof. More particularly, it may induce an effective apoptosis of cancer cells by inhibition of an Enigma expression or an Enigma activity which induces Mdm2 destabilization and p53 activity; it may assess the prognosis of anti-cancer therapy by determining that Enigma, which is induced by SRF, is overexpressed in cancer tissues with Mdm2; it may screen anti-cancer activity substances by selecting a factor to inhibit specific binding between Enigma and Mdm2. Enigma-Mdm2 interaction and Enigma expression regulation may be utilized usefully for preventing cancers and developing therapeutic methods and anti-cancer agents.Type: ApplicationFiled: September 22, 2011Publication date: January 19, 2012Inventors: Cho-Rok Jung, Dong-Soo Im, Jung-Hwa Lim, Yoon Jung Choi
-
Patent number: 8088750Abstract: The present invention relates to Enigma (PDLIM7)-Mdm2 interaction and use thereof. More particularly, it may induce an effective apoptosis of cancer cells by inhibition of an Enigma expression or an Enigma activity which induces Mdm2 destabilization and p53 activity; it may assess the prognosis of anti-cancer therapy by determining that Enigma, which is induced by SRF, is overexpressed in cancer tissues with Mdm2; it may screen anti-cancer activity substances by to selecting a factor to inhibit specific binding between Enigma and Mdm2. Enigma-Mdm2 interaction and Enigma expression regulation may be utilized usefully for preventing cancers and developing therapeutic methods and anti-cancer agents.Type: GrantFiled: February 11, 2010Date of Patent: January 3, 2012Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Cho-Rok Jung, Dong-Soo Im, Jung-Hwa Lim, Yoon Jung Choi
-
Publication number: 20110213016Abstract: The present invention relates to the E2EPF UCP-VHL interaction and the uses thereof, more precisely a method for increasing or reducing VHL activity or level by regulating UCP activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of UCP activity is accomplished by any UCP activity inhibitor selected from a group consisting of a small interfering RNA (RNAi), an antisense oligonucleotide, and a polynucleotide complementarily binding to mRNA of UCP, a peptide, a peptide mimetics and an antibody, and a low molecular compound. In the meantime, the increase of angiogenesis is accomplished by the following mechanism; UCP over-expression is induced by a gene carrier and thus endogenous VHL is reduced, leading to the stabilization of HIF-1? which enhances VEGF activation based on the HIF-1? stabilization.Type: ApplicationFiled: May 28, 2010Publication date: September 1, 2011Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Dong-Soo Im, Cho-Rok Jung, Kyung-Sun Hwang
-
Publication number: 20100239566Abstract: The present invention relates to Enigma (PDLIM7)-Mdm2 interaction and use thereof. More particularly, it may induce an effective apoptosis of cancer cells by inhibition of an Enigma expression or an Enigma activity which induces Mdm2 destabilization and p53 activity; it may assess the prognosis of anti-cancer therapy by determining that Enigma, which is induced by SRF, is overexpressed in cancer tissues with Mdm2; it may screen anti-cancer activity substances by to selecting a factor to inhibit specific binding between Enigma and Mdm2. Enigma-Mdm2 interaction and Enigma expression regulation may be utilized usefully for preventing cancers and developing therapeutic methods and anti-cancer agents.Type: ApplicationFiled: February 11, 2010Publication date: September 23, 2010Inventors: Cho-Rok Jung, Dong-Soo Im, Jung-Hwa Lim, Yoon Jung Choi
-
Publication number: 20080269158Abstract: The present invention relates to the E2EPF UCP-VHL interaction and the uses thereof, more precisely a method for increasing or reducing VHL activity or level by regulating UCP activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of UCP activity is accomplished by any UCP activity inhibitor selected from a group consisting of a small interfering RNA (RNAi), an antisense oligonucleotide, and a polynucleotide complementarily binding to mRNA of UCP, a peptide, a peptide mimetics and an antibody, and a low molecular compound. In the meantime, the increase of angiogenesis is accomplished by the following mechanism; UCP over-expression is induced by a gene carrier and thus endogenous VHL is reduced, leading to the stabilization of HIF-1? which enhances VEGF activation based on the HIF-1? stabilization.Type: ApplicationFiled: November 13, 2006Publication date: October 30, 2008Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Dong-Soo Im, Cho-Rok Jung, Kyung-Sun Hwang